NCYT.L

Novacyt S.A.
Novacyt S.A. - Notice of rescheduled AGM
26th June 2024, 13:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0112U
Novacyt S.A.
26 June 2024
 


 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Notice of rescheduled AGM

 

AGM to be held online on Thursday 18 July

 

Paris, France, and Eastleigh and Manchester, UK - 26 June 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that the Company's Annual General Meeting (AGM), due to take place earlier today, will be rescheduled and held exclusively as an open online meeting on Thursday 18 July at 1pm BST/2pm CEST.

 

To function as a procedural meeting, the AGM requires a sufficient number of shareholder votes to constitute a quorum to ensure the AGM is validly held in accordance with French corporate law. This threshold has not been met, therefore, in accordance with Article 19 of Novacyt articles of association, the AGM has been rescheduled.

 

The agenda will remain the same as in the first convening and the AGM will comprise of both ordinary and extraordinary resolutions.

 

Shareholders can register to view the AGM via the online meeting platform by visiting https://reg.lumiengage.com/novacyt-sa-agm-2024/novacytagm2024/Site/Register. Registrations must be accompanied by formal evidence of shareholding.

 

Forms of Proxy already completed and submitted and votes cast by electronic means for the first AGM remain valid for all meetings subsequently convened with the same agenda (art. R. 225-77 of the French commercial code). Full details of dates concerning voting will follow in due course.

 

Contacts

 

Novacyt SA

https://novacyt.com/investors

Lyn Rees, Chief Executive Officer

 Via Walbrook PR

Steve Gibson, Chief Financial Officer 

 


SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

+44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)




Deutsche Numis (Joint Broker)

+44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Michael Palser




Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

 +33 (1) 42 22 10 10
 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com


Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Paul McManus /

Phillip Marriage / Alice Woodings

+44 (0)20 7933 8780 or novacyt@walbrookpr.com

+44 (0)7796 794 663 / +44 (0)7980 541 893

 +44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

 

The Company is divided into three business segments:

 

Clinical

Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:

·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests

·    Precision Medicine: DPYD genotyping assay

·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

 

Instrumentation

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

·  Ranger® Technology: automated DNA sample preparation and target enrichment technology

·     MyGo: real-time quantitative PCR (qPCR) instruments

 

Research Use Only 

Range of services for the life sciences industry:

·    Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry

·  Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAGZGZVFVNGDZM]]>
TwitterFacebookLinkedIn